Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs
about
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyEffects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathyCutaneous neuropathy in Parkinson's disease: a window into brain pathology.An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.Continuous drug delivery in Parkinson's disease.New treatments for the motor symptoms of Parkinson's disease.Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management.The safety of istradefylline for the treatment of Parkinson's disease.Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.Clinical drug research in chronic central neurodegenerative disorders.Novel Levodopa Formulations for Parkinson's Disease.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
P2860
Q30366253-FF3496E2-59B8-4105-A851-70F5EA84919CQ33695388-FDFFA622-135A-4336-8E10-D8E8CCA5BCE1Q33764504-4FD8F6CB-5A8C-46E7-86DF-341504D879FDQ33890861-84A98695-9CBD-48E7-8ACF-0A3947C57007Q34390800-B0F45252-DAF1-4D02-B2ED-47DD90549C35Q34443682-A2A42492-7BE6-43AD-9F40-4DF5348C37FAQ38194569-E59D9351-4906-4788-A91C-D716ECBCE99DQ38244310-F9FF1F1E-DA57-4EA0-8070-7CB39A143FACQ38353204-A8AE909E-F4E7-4326-950E-56EEBA157163Q38742792-72805330-2BE7-4CB7-B2C5-469598BCBCDDQ38763831-C4B9B811-D9B5-42A9-A715-5F89208F8A7FQ38981419-CE03B89D-402E-4DE8-B0B4-DC69A7E2B296Q47962428-1BC1FD83-DC9D-467F-B232-BBE4C811F914Q48287261-2C65CDEA-F625-4C47-8503-F07F99730604Q52855994-AEBCC995-CEDD-46C9-BF43-52FEF85A6DB4Q52880488-D6F259CB-40FE-4DFC-AECE-91A66BE07BE1Q53143036-4EE04764-52D5-4A2B-B317-943EF30BE649Q53661046-4776F599-2917-4AB9-B8A7-B751C31B5632
P2860
Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@ast
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@en
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@nl
type
label
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@ast
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@en
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@nl
prefLabel
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@ast
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@en
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@nl
P2093
P2860
P1433
P1476
Neuropathy in Parkinson's dise ...... opa infusion versus oral drugs
@en
P2093
Birol Taskin
Constanze Jugel
Fabian Klostermann
Felicitas Ehlen
Frank Marzinzik
P2860
P304
P356
10.1371/JOURNAL.PONE.0066639
P407
P577
2013-01-01T00:00:00Z